Calidi Biotherapeutics Stock Revenue
| CLDI Stock | 1.55 0.01 0.65% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Calidi Biotherapeutics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year |
Calidi | Revenue | Build AI portfolio with Calidi Stock |
Calidi Biotherapeutics Company Revenue Analysis
Calidi Biotherapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Calidi
Projected quarterly revenue analysis of Calidi Biotherapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Calidi Biotherapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Calidi Biotherapeutics' stock price.
Calidi Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Calidi Biotherapeutics is extremely important. It helps to project a fair market value of Calidi Stock properly, considering its historical fundamentals such as Revenue. Since Calidi Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Calidi Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Calidi Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Calidi Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Calidi Biotherapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Calidi Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Calidi Biotherapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Calidi Biotherapeutics could also be used in its relative valuation, which is a method of valuing Calidi Biotherapeutics by comparing valuation metrics of similar companies.Calidi Biotherapeutics is currently under evaluation in revenue category among its peers.
Calidi Fundamentals
| Return On Asset | -1.58 | ||||
| Current Valuation | 7.08 M | ||||
| Shares Outstanding | 5.35 M | ||||
| Shares Owned By Insiders | 20.13 % | ||||
| Shares Owned By Institutions | 4.16 % | ||||
| Number Of Shares Shorted | 120.34 K | ||||
| Price To Book | 4.73 X | ||||
| Price To Sales | 50.83 X | ||||
| Gross Profit | 31 K | ||||
| EBITDA | (21.78 M) | ||||
| Net Income | (22.21 M) | ||||
| Total Debt | 7.04 M | ||||
| Book Value Per Share | 0.58 X | ||||
| Cash Flow From Operations | (19.69 M) | ||||
| Short Ratio | 0.75 X | ||||
| Earnings Per Share | (0.20) X | ||||
| Target Price | 120.0 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 8.24 M | ||||
| Total Asset | 14.18 M | ||||
| Retained Earnings | (121.72 M) | ||||
| Working Capital | 731 K | ||||
| Net Asset | 14.18 M |
About Calidi Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Calidi Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Calidi Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Calidi Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Check out Calidi Biotherapeutics Piotroski F Score and Calidi Biotherapeutics Altman Z Score analysis. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calidi Biotherapeutics. If investors know Calidi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Calidi Biotherapeutics is measured differently than its book value, which is the value of Calidi that is recorded on the company's balance sheet. Investors also form their own opinion of Calidi Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calidi Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calidi Biotherapeutics' market value can be influenced by many factors that don't directly affect Calidi Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calidi Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calidi Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calidi Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.